Femasys Inc (Nasdaq:FEMY), a biomedical innovator focused on addressing unmet needs in women's health, announced on Thursday that it has received Conformité Européene (CE) mark certification for its FemBloc delivery system, a non-surgical approach to permanent birth control for women.
This approval represents a significant milestone in the availability of FemBloc, which offers a minimally invasive, non-surgical alternative to traditional sterilisation methods.
The FemBloc system delivers a proprietary synthetic tissue adhesive to both fallopian tubes, creating non-functional scar tissue that permanently blocks the tubes. Over time, the blended polymer fully degrades.
The approval follows a successful G12 Special MDR Audit for Class III devices, with the European Medical Agency (EMA) expected to complete its review by mid-2025.
According to Femasys, its innovation provides a lower-cost, less risky option for permanent birth control, offering a significant advancement over surgical procedures.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study